ArticleAntibiotics (Basel, Switzerland)2020
Antimicrobial and Antibiofilm Capacity of Chitosan Nanoparticles against Wild Type Strain of
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 70 citations in OpenAlex.
- Piperazine linked chitosan schiff base nanoparticles as a novel antibiofilm and antibacterial strategy against clinically relevant pathogens.Scientific reports · 2026Article
- Chitosan nanoparticles as a sustainable antibacterial approach for inhibitingOpen veterinary journal · 2026Article
- Modern therapeutic strategies to mitigate biofilm-associated infection in livestock organisms.Antonie van Leeuwenhoek · 2025Review
- Multiphase antibiofilm potential of shrimp-shell-derived chitosan nanoparticles against Aeromonas hydrophila isolated from tropical aquaculture environments.Veterinary world · 2025Article
- Comprehensive Prevention and Control of Mastitis in Dairy Cows: From Etiology to Prevention.Veterinary sciences · 2025Review
- Nanoparticles as an alternative treatment for bovine mastitis-A review.Animal bioscience · 2025Article
- Polyhexamethylene Biguanide Nanoparticles Inhibit Biofilm Formation by Mastitis-CausingVeterinary sciences · 2025Article
- Antimicrobial and Antibiofilm Activity of Chitosan Nanoparticles AgainstPharmaceutics · 2025Article
- Recent Advances in the Preparation, Antibacterial Mechanisms, and Applications of Chitosan.Journal of functional biomaterials · 2024Review
- Green synthesis of chitosan nanoparticles using3 Biotech · 2024Article
- Antivirulence activities of Rutin-loaded chitosan nanoparticles against pathogenic Staphylococcus aureus.BMC microbiology · 2024Article
- From Herd Health to Public Health: Digital Tools for Combating Antibiotic Resistance in Dairy Farms.Antibiotics (Basel, Switzerland) · 2024Review
- Exploring the antimicrobial potential of chitosan nanoparticles: synthesis, characterization and impact onNanoscale advances · 2024Article
- Emerging Approaches for Mitigating Biofilm-Formation-Associated Infections in Farm, Wild, and Companion Animals.Pathogens (Basel, Switzerland) · 2024Review
- Research and Application of Chitosan Nanoparticles in Orthopedic Infections.International journal of nanomedicine · 2024Review
- Enzyme-Linked Lipid Nanocarriers for Coping Pseudomonal Pulmonary Infection. Would Nanocarriers Complement Biofilm Disruption or Pave Its Road?International journal of nanomedicine · 2024Article
- Strategies for the Preparation of Chitosan Derivatives for Antimicrobial, Drug Delivery, and Agricultural Applications: A Review.Molecules (Basel, Switzerland) · 2023Review
- Chitosan and Its Derivatives: Preparation and Antibacterial Properties.Materials (Basel, Switzerland) · 2023Review
- Green fabrication of chitosan nanoparticles using Lavendula angustifolia, optimization, characterization and in‑vitro antibiofilm activity.Scientific reports · 2023Article
- Advances in Diagnostic Approaches and Therapeutic Management in Bovine Mastitis.Veterinary sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine mastitis (BM) is the most prevalent bacterial infection in the livestock sector, affecting the dairy industry greatly. The prevention and treatment of this disease is mainly made via antibiotics, but the increasing antimicrobial resistance of pathogens has affected the efficiency of conventional drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.